New diagnostic techniques in staging in the surgical treatment of cutaneous malignant melanoma

European Journal of Surgical Oncology

Volumn 28, Issue 7, 2002, Pages 692-700

  Cobben, D C P ^a,b   Koopal, S ^a   Tiebosch, A T M G ^a   Jager, P L ^a,b   Elsinga, P H ^b   Wobbes, Th ^a   Hoekstra, H J ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

Melanoma; Pathology; Positron emission tomography; Sentinel lymph node biopsy

Indexed keywords

ALPHA2B INTERFERON; FLUORODEOXYGLUCOSE F 18; MELPHALAN; TUMOR MARKER;

CANCER ADJUVANT THERAPY; CANCER RESEARCH; CANCER STAGING; CANCER SURGERY; DIAGNOSTIC PROCEDURE; HIGH RISK PATIENT; HUMAN; HYPERTHERMIC THERAPY; IMMUNOHISTOCHEMISTRY; LYMPH NODE DISSECTION; MELANOMA; METASTASIS; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; SENTINEL LYMPH NODE BIOPSY; SKIN CANCER;

EID: 0036880672     PISSN: 07487983     EISSN: None     Source Type: Journal    
DOI: 10.1053/ejso.2002.1319     Document Type: Review

References (112)

1. Visser O, Coebergh JWW, Schouten LJM, Dijck van JAAM. Incidence of cancer in the Netherlands 1997; Ninth report of the Netherlands cancer registry. Dutch Cancer Registry 2001.
2. Jemal A, Devesa SS, Hartge P, Tucker MA. Recent trends in cutaneous melanoma incidence among whites in the United States. J Natl Cancer Inst 2001; 93: 678-83.
3. Chang AE, Karnell LH, Menck HR. The National Cancer Data Base report on cutaneous and noncutaneous melanoma: a summary of 84836 cases from the past decade. The American College of Surgeons Commission on Cancer and the American Cancer Society. Cancer 1998; 83: 1664-78.
4. Epstein DS, Lange JR, Gruber SB, Mofid M, Koch SE. Is physician detection associated with thinner melanomas? JAMA 1999; 281: 640-3.
5. Hofer SO, Molema G, Hermens RA, Wanebo HJ, Reichner JS, Hoekstra HJ. The effect of surgical wounding on tumour development. Eur J Surg Oncol 1999; 25: 231-43.
6. Veronesi U, Cascinelli N, Adamus J, Balch C, Bandiera D, Barchuk A et al. Thin stage I primary cutaneous malignant melanoma. Comparison of excision with margins of 1 or 3 cm. N Engl J Med 1988; 318: 1159-62.
7. Balch CM, Urist MM, Karakousis CP, Smith TJ, Temple WJ, Drzewiecki K et al. Efficacy of 2-cm surgical margins for intermediate-thickness melanomas (1 to 4mm). Results of a multi-institutional randomized surgical trial. Ann Surg 1993; 218: 262-7.
8. Balch CM, Soong SJ, Smith T, Ross MI, Urist MM, Karakousis CP et al. Long-term results of a prospective surgical trial comparing 2 cm vs. 4 cm excision margins for 740 patients with 1-4 mm melanomas. Ann Surg Oncol 2001; 8: 101-8.
9. NIH Consensus Conference. Diagnosis and treatment of early melanoma. JAMA 1992; 268: 314-9.
10. Kroon BB, Nieweg OE, Hoekstra HJ, Lejeune FJ. Principles and guidelines for surgeons: management of cutaneous malignant melanoma. European Society of Surgical Oncology Brussels. Eur J Surg Oncol 1997; 23: 550-8.
11. Cascinelli N. Margin of resection in the management of primary melanoma. Semin Surg Oncol 1998; 14: 272-5.
12. Randomised trial of width of excision of thick cutaneuous melanoma. Melanoma Study Group (MSG)/British Association of Plastic Surgeons 2001.
13. Veronesi U, Adamus J, Bandiera DC, Brennhovd IO, Caceres E, Cascinelli N et al. Inefficacy of immediate node dissection in stage I melanoma of the limbs. N Engl J Med 1977; 297: 627-30.
14. Sim FH, Taylor WF, Ivins JC, Pritchard DJ, Soule EH. A prospective randomized study of the efficacy of routine elective lymphadenectomy in management of malignant melanoma. Preliminary results. Cancer 1978; 41: 948-56.
15. Balch CM, Soong SJ, Bartolucci AA, Urist MM, Karakousis CP, Smith TJ et al. Efficacy of an elective regional lymph node dissection of 1 to 4 mm thick melanomas for patients 60 years of age and younger. Ann Surg 1996; 224: 255-63.
16. Cascinelli N, Morabito A, Santinami M, MacKie RM, Belli F. Immediate or delayed dissection of regional nodes in patients with melanoma of the trunk: a randomised trial. WHO Melanoma Program. Lancet 1998; 351: 793-6.
17. Schraffordt Koops HS, Vaglini M, Suciu S, Kroon BB, Thompson JF, Gohl J et al. Prophylactic isolated limb perfusion for localized, high-risk limb melanoma: results of a multicenter randomized phase III trial. European Organization for Research and Treatment of Cancer Malignant Melanoma Cooperative Group Protocol 18832, the World Health Organization Melanoma Program Trial 15, and the North American Perfusion Group Southwest Oncology Group-8593. J Clin Oncol 1998; 16: 2906-12.
18. Steinmann G, Eggermont AM. Boehringer Ingelheim trial 152.70. An open randomised, prospective trial to compare the efficacy and safety of TNF-alfa and melphalan with melphalan alone via isolated limb perfusion for metastatic melanoma of the limb (stage IIA, IIB, IIIA and IIIAB). Boehringer Ingelheim trial 152 70 1999.
19. Fraker DL. NCI-trial: Phase III randomized study of hyperthermic isolated limb perfusion and melphalan with or without tumor necrosis factor in patients with localized, advanced, extremity melanoma. ACOSOG-Z0020 2001.
20. Baas PC, Hoekstra HJ, Schraffordt Koops H, Oosterhuis JW, Weele van der LT, Oldhoff J. Results of hyperthermic isolated regional perfusion of locally metastasized melanoma of the lower extremity with melphalan with or without dactinomycin using different dosage methods. Reg Cancer Treat 1989; 2: 87-91.
21. Hafstrom L, Rudenstam CM, Blomquist E, Ingvar C, Jonsson PE, Lagerlof B et al. Regional hyperthermic perfusion with melphalan after surgery for recurrent malignant melanoma of the extremities. Swedish Melanoma Study Group. J Clin Oncol 1991; 9: 2091-4.
22. Hoekstra HJ, Schraffordt Koops HS, de Vries EGE, van Weerden TW, Oldhoff J. Toxicity of hyperthermic isolated limb perfusion with cisplatin for recurrent melanoma of the lower extremity after previous perfusion treatment. Cancer 1993; 72: 1224-9.
23. Brady MS. Phase II Study of Isolated Limb Infusion with Melphalan and Dactinomycin in Patients with Primary or Recurrent, Unresectable Regional Melanoma or Soft Tissue Sarcoma of the Extremity. NCI-trial 2001.
24. Morton DL, Bostick PJ. Will the true sentinel node please stand? Ann Surg Oncol 1999; 6: 12-4.
25. Keshtgar MR, Ell PJ. Sentinel lymph node detection and imaging. Eur J Nucl Med 1999; 26: 57-67.
26. Nieweg OE, Tanis PJ, Kroon BB. The definition of a sentinel node. Ann Surg Oncol 2001; 8: 538-41.
27. Robinson DS, Sample WF, Fee HJ, Holmes C, Morton DL. Regional lymphatic drainage in primary malignant melanoma of the trunk determined by colloidal gold scanning. Surg Forum 1977; 28: 147-8.
28. Morton DL, Wen DR, Wong JH, Economou JS, Cagle LA, Storm FK et al. Technical details of intraoperative lymphatic mapping for early stage melanoma. Arch Surg 1992; 127: 392-9.
29. Kapteijn BA, Nieweg OE, Liem I, Mooi WJ, Balm AJ, Muller SH et al. Localizing the sentinel node in cutaneous melanoma: gamma probe detection versus blue dye. Ann Surg Oncol 1997; 4: 156-60.
30. Koopal SA, Tiebosch ATMG, Piers AD, Schraffordt Koops H, Hoekstra HJ. Frozen section analysis of sentinel lymph nodes in melanoma patients. Cancer 2000; 89: 1720-5.
31. Morton DL, Thompson JF, Essner R, Elashoff R, Stern SL, Nieweg OE et al. Validation of the accuracy of intraoperative lymphatic mapping and sentinel lymphadenectomy for early-stage melanoma: a multicenter trial. Multicenter Selective Lymphadenectomy Trial Group. Ann Surg 1999; 230: 453-63.
32. Tanis PJ, Boom RP, Koops HS, Faneyte IF, Peterse JL, Nieweg OE et al. Frozen section investigation of the sentinel node in malignant melanoma and breast cancer. Ann Surg Oncol 2001; 8: 222-6.
33. Berman CG, Norman J, Cruse CW, Reintgen DS, Clark RA. Lymphoscintigraphy in malignant melanoma. Ann Plast Surg 1992; 28: 29-32.
34. Albertini JJ, Cruse CW, Rapaport D, Wells K, Ross M, DeConti R et al. Intraoperative radio-lympho-scintigraphy improves sentinel lymph node identification for patients with melanoma. Ann Surg 1996; 223: 217-24.
35. Gershenwald JE, Thompson W, Mansfield PF, Lee JE, Colome MI, Tseng CH et al. Multi-institutional melanoma lymphatic mapping experience: the prognostic value of sentinel lymph node status in 612 stage I or II melanoma patients. J Clin Oncol 1999; 17: 976-83.
36. Morton DL, Wen DR, Cochran AJ. Management of early-stage melanoma by intra-operative lymphatic mapping and selective lymphadenectomy or 'watch and see'. Surg Oncol Clin N Am 1992; 247-59.
37. Reintgen D, Cruse CW, Wells K, Berman C, Fenske N, Glass F et al. The orderly progression of melanoma nodal metastases. Ann Surg 1994; 220: 759-67.
38. Gershenwald JE, Colome MI, Lee JE, Mansfield PF, Tseng C, Lee JJ et al. Patterns of recurrence following a negative sentinel lymph node biopsy in 243 patients with stage I or II melanoma. J Clin Oncol 1998; 16: 2253-60.
39. Balch CM, Buzaid AC, Atkins MB, Cascinelli N, Coit DG, Fleming ID et al. A new American Joint Committee on Cancer staging system for cutaneous melanoma. Cancer 2000; 88: 1484-91.
40. Balch CM, Buzaid AC, Soong SJ, Atkins MB, Cascinelli N, Coit DG et al. Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol 2001; 19: 3635-48.
41. Balch CM, Soong SJ, Gershenwald JE, Thompson JF, Reintgen DS, Cascinelli N et al. Prognostic factors analysis of 17600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system. J Clin Oncol 2001; 19: 3622-34.
42. Reintgen D, Rapaport D, Tanabe KK, Ross M. Lymphatic mapping and sentinel node biopsy in patients with malignant melanoma. J Fla Med Assoc 1997; 84: 188-93.
43. Uren RF, Howman-Giles R, Thompson JF, Quinn MJ, O'Brien C, Shaw HM et al. Lymphatic drainage to triangular intermuscular space lymph nodes in melanoma on the back. J Nucl Med 1996; 37: 964-6.
44. Norman J, Cruse CW, Espinosa C, Cox C, Berman C, Clark R et al. Redefinition of cutaneous lymphatic drainage with the use of lymphoscintigraphy for malignant melanoma. Am J Surg 1991; 162: 432-7.
45. Uren RF, Howman-Giles RB, Shaw HM, Thompson JF, McCarthy WH. Lymphoscintigraphy in high-risk melanoma of the trunk: predicting draining node groups, defining lymphatic channels and locating the sentinel node. J Nucl Med 1993; 34: 1435-40.
46. Uren RF, Howman-Giles RB, Thompson JF, Shaw HM, McCarthy WH. Lymphatic drainage from peri-umbilical skin to internal mammary nodes. Clin Nucl Med 1995; 20: 254-5.
47. Karakousis CP, Grigoropoulos P. Sentinel node biopsy before and after wide excision of the primary melanoma. Ann Surg Oncol 1999; 6: 785-9.
48. McMasters KM, Reintgen DS, Ross MI, Wong SL, Gershenwald JE, Krag DN et al. Sentinel lymph node biopsy for melanoma: how many radioactive nodes should be removed? Ann Surg Oncol 2001; 8: 192-7.
49. Uren RF, Howman-Giles R, Thompson JF, McCarthy WH, Quinn MJ, Roberts JM et al. Interval nodes: the forgotten sentinel nodes in patients with melanoma. Arch Surg 2000; 135: 1168-72.
50. Thelmo MC, Morita ET, Treseler PA, Nguyen LH, Allen RE, Jr, Sagebiel RW et al. Micrometastasis to in-transit lymph nodes from extremity and truncal malignant melanoma. Ann Surg Oncol 2001; 8: 444-8.
51. Morton DL. NCI trial: Multicenter Selective Lymphadenectomy Trial. NCI grant POI CA 29605 2001.
52. McMasters KM, Reintgen DD, Edwards MJ, Cerrito P, Krag DN, Ross MI. Sunbelt Melanoma Trial: a multicenter trial of adjuvant interferon alfa-2b for melanoma in patients with early lymph node metastasis detected by lymphatic mapping and sentinel lymph node biopsy. Sunbelt Melanoma Trial (SMT) 1996.
53. Thomas JM, Patocskai EJ. The argument against sentinel node biopsy for malignant melanoma. BMJ 2000; 321: 3-4.
54. McMasters KM, Reintgen DS, Ross MI, Gershenwald JE, Edwards MJ, Sober A et al. Sentinel lymph node biopsy for melanoma: controversy despite widespread agreement. J Clin Oncol 2001; 19: 2851-5.
55. Eggermont AMM, Kleeberg UR, Ruiter DJ, Suciu S. European Organization for Research and Treatment of Cancer Melanoma Group trial experience with more than 2000 patients, evaluating adjuvant treatment with low or intermediate doses of interferon alpha-2b. ASCO Conference 2001.
56. Kirkwood JM. Adjuvant therapy of high-risk resected melanoma: relapse-free and overall survival effects of high dose interferon alpha-2b in randomized controlled multicenter trials E1684 and E2696 and intergroup trials E1690 and E1694. ASCO Conference 2001.
57. Kirkwood JM, Ibrahim JG, Sosman JA, Sondak VK, Agarwala SS, Ernstoff MS, Rao U. High-dose interferon alfa-2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH/QS-21 vaccine in patients with resected stage IIB-III melanoma: results of intergroup trial E1694/S9512/C509801. J Clin Oncol 2001; 19: 2370-80.
58. Cascinelli N, Belli F, MacKie RM, Santinami M, Bufalino R, Morabito A. Effect of long-term adjuvant therapy with interferon alpha-2a in patients with regional node metastases; from cutaneous melanoma: a randomised trial. Lancet 2001; 358: 866-9.
59. Holder WD, Jr, White RL, Jr, Zuger JH, Easton EJ, Jr, Greene FL. Effectiveness of positron emission tomography for the detection of melanoma metastases. Ann Surg 1998; 227: 764-9.
60. Eigtved A, Andersson AP, Dahlstrom K, Rabol A, Jensen M, Holm S et al. Use of fluorine-18 fluorodeoxyglucose positron emission tomography in the detection of silent metastases from malignant melanoma. Eur J Nucl Med 2000; 27: 70-5.
61. Som P, Atkins HL, Bandoypadhyay D, Fowler JS, MacGregor RR, Matsui K et al. A fluorinated glucose analog, 2-fluoro-2-deoxy-D-glucose (F-18): nontoxic tracer for rapid tumor detection. J Nucl Med 1980; 21: 670-5.
62. Gritters LS, Francis IR, Zasadny KR, Wahl RL. Initial assessment of positron emission tomography using 2-fluorine-18-fluoro-2-deoxy-D-glucose in the imaging of malignant melanoma. J Nucl Med 1993; 34: 1420-7.
63. Damian DL, Fulham MJ, Thompson E, Thompson JF. Positron emission tomography in the detection and management of metastatic melanoma. Melanoma Res 1996; 6: 325-9.
64. Wagner JD, Schauwecker D, Hutchins G, Coleman JJ, III. Initial assessment of positron emission tomography for detection of nonpalpable regional lymphatic metastases in melanoma. J Surg Oncol 1997; 64: 181-9.
65. Rinne D, Baum RP, Hor G, Kaufmann R. Primary staging and follow-up of high risk melanoma patients with whole-body 18F-fluorodeoxyglucose positron emission tomography: results of a prospective study of 100 patients. Cancer 1998; 82: 1664-71.
66. Wagner JD, Schauwecker D, Davidson D, Coleman JJ, III, Saxman S, Hutchins G et al. Prospective study of fluorodeoxyglucose-positron emission tomography imaging of lymph node basins in melanoma patients undergoing sentinel node biopsy. J Clin Oncol 1999; 17: 1508-15.
67. Macfarlane DJ, Sondak V, Johnson T, Wahl RL. Prospective evaluation of 2-[18F]-2-deoxy-D-glucose positron emission tomography in staging of regional lymph nodes in patients with cutaneous malignant melanoma. J Clin Oncol 1998; 16: 1770-6.
68. Acland KM, Healy C, Calonje E, O'Doherty M, Nunan T, Page C et al. Comparison of positron emission tomography scanning and sentinel node biopsy in the detection of micrometastases of primary cutaneous malignant melanoma. J Clin Oncol 2001; 19: 2674-8.
69. Wagner JD, Schauwecker DS, Davidson D, Wenck S, Jung SH, Hutchins G. FDG-PET sensitivity for melanoma lymph node metastases is dependent on tumor volume. J Surg Oncol 2001; 77: 237-42.
70. Tyler DS, Onaitis M, Kherani A, Hata A, Nicholson E, Keogan M et al. Positron emission tomography scanning in malignant melanoma. Cancer 2000; 89: 1019-25.
71. Schwimmer J, Essner R, Patel A, Jahan SA, Shepherd JE, Park K et al. A review of the literature for whole-body FDG PET in the management of patients with melanoma. Q J Nucl Med 2000; 44: 153-67.
72. Mijnhout GS, Hoekstra OS, van Tulder MW, Teule GJ, Deville WL. Systematic review of the diagnostic accuracy of (18)F-fluoro-deoxyglucose positron emission tomography in melanoma patients. Cancer 2001; 91: 1530-42.
73. Robert ME, Wen DR, Cochran AJ. Pathological evaluation of the regional lymph nodes in malignant melanoma. Semin Diagn Pathol 1993; 10: 102-15.
74. Bostick PJ, Morton DL, Turner RR, Huynh KT, Wang HJ, Elashoff R et al. Prognostic significance of occult metastases detected by sentinel lymphadenectomy and reverse transcriptase-polymerase chain reaction in early-stage melanoma patients. J Clin Oncol 1999; 17: 3238-44.
75. Jung R, Ahmad-Nejad P, Wimmer M, Gerhard M, Wagener C, Neumaier M. Quality management and influential factors for the detection of single metastatic cancer cells by reverse transcriptase polymerase chain reaction. Eur J Clin Chem Clin Biochem 1997; 35: 3-10.
76. Djukanovic D, Hofmann U, Sucker A, Rittgen W, Schadendorf D. Comparison of S100 protein and MIA protein as serum marker for malignant melanoma. Anticancer Res 2000; 20: 2203-7.
77. Kelley MC, Gupta RK, Hsueh EC, Yee R, Stern S, Morton DL. Tumor-associated antigen TA90 immune complex assay predicts recurrence and survival after surgical treatment of stage I-III melanoma. J Clin Oncol 2001; 19: 1176-82.
78. Hatta N, Takata M, Takehara K, Ohara K. Polymerase chain reaction and immunohistochemistry frequently detect occult melanoma cells in regional lymph nodes of melanoma patients. J Clin Pathol 1998; 51: 597-601.
79. Cochran AJ, Wen DR, Morton DL. Occult tumor cells in the lymph nodes of patients with pathological stage I malignant melanoma. An immunohistological study. Am J Surg Pathol 1988; 12: 612-18.
80. Bautista NC, Cohen S, Anders KH. Benign melanocytic nevus cells in axillary lymph nodes. A prospective incidence and immunohistochemical study with literature review. Am J Clin Pathol 1994; 102: 102-8.
81. Clarkson KS, Sturdgess IC, Molyneux AJ. The usefulness of tyrosinase in the immunohistochemical assessment of melanocytic lesions: a comparison of the novel T311 antibody (anti-tyrosinase) with S-100, HMB45, and A103 (anti-melan-A). J Clin Pathol 2001; 54: 196-200.
82. Wang X, Heller R, VanVoorhis N, Cruse CW, Glass F, Fenske N et al. Detection of submicroscopic lymph node metastases with polymerase chain reaction in patients with malignant melanoma. Ann Surg 1994; 220: 768-74.
83. Reintgen D, Albertini J, Berman C, Cruse CW, Fenske N, Glass LF et al. Accurate nodal staging of malignant melanoma. Cancer Control 1995; 2: 405-14.
84. Blaheta HJ, Schittek B, Breuninger H, Sotlar K, Ellwanger U, Thelen MH et al. Detection of melanoma micrometastasis in sentinel nodes by reverse transcription-polymerase chain reaction correlates with tumor thickness and is predictive of micrometastatic disease in the lymph node basin. Am J Surg Pathol 1999; 23: 822-8.
85. Blaheta HJ, Schittek B, Breuninger H, Garbe C. Detection of micrometastasis in sentinel lymph nodes of patients with primary cutaneous melanoma. Recent Results Cancer Res 2001; 158: 137-46.
86. Palmieri G, Ascierto PA, Cossu A, Mozzillo N, Motti ML, Satriano SM et al. Detection of occult melanoma cells in paraffin-embedded histologically negative sentinel lymph nodes using a reverse transcriptase polymerase chain reaction assay. J Clin Oncol 2001; 19: 1437-43.
87. Goydos JS, Ravikumar TS, Germino FJ, Yudd A, Bancila E. Minimally invasive staging of patients with melanoma: sentinel lymphadenectomy and detection of the melanoma-specific proteins MART-1 and tyrosinase by reverse transcriptase polymerase chain reaction. J Am Coll Surg 1998; 187: 182-8.
88. Shivers SC, Wang X, Li W, Joseph E, Messina J, Glass LF et al. Molecular staging of malignant melanoma: correlation with clinical outcome. JAMA 1998; 280: 1410-15.
89. Chelly J, Concordet JP, Kaplan JC, Kahn A. Illegitimate transcription: transcription of any gene in any cell type. Proc Natl Acad Sci U S A 1989; 86: 2617-21.
90. Battyani Z, Xerri L, Hassoun J, Bonerandi JJ, Grob JJ. Tyrosinase gene expression in human tissues. Pigment Cell Res 1993; 6: 400-5.
91. Shivers SC, Li W, Haddad F, Reintgen DS. Molecular staging of melanoma. Ann Surg Oncol 1999; 6: 225-6.
92. Calogero A, Timmer-Bosscha H, Schraffordt Koops H, Tiebosch AT, Mulder NH, Hospers GA. Limitations of the nested reverse transcriptase polymerase chain reaction on tyrosinase for the detection of malignant melanoma micrometastases in lymph nodes. Br J Cancer 2000; 83: 184-7.
93. Brouwenstijn N, Slager EH, Bakker AB, Schreurs MW, Van der Spek CW, Adema GJ et al. Transcription of the gene encoding melanoma-associated antigen gp100 in tissues and cell lines other than those of the melanocytic lineage. Br J Cancer 1997; 76: 1562-6.
94. Neumaier M, Gerhard M, Wagener C. Diagnosis of micrometastases by the amplification of tissue-specific genes. Gene 1995; 159: 43-7.
95. Dingemans AM, Brakenhoff RH, Postmus PE, Giaccone G. Detection of cytokeratin-19 transcripts by reverse transcriptase-polymerase chain reaction in lung cancer cell lines and blood of lung cancer patients. Lab Invest 1997; 77: 213-20.
96. de Vries TJ, Fourkour A, Wobbes T, Verkroost G, Ruiter DJ, van Muijen GN. Heterogeneous expression of immunotherapy candidate proteins gp100, MART-1, and tyrosinase in human melanoma cell lines and in human melanocytic lesions. Cancer Res 1997; 57: 3223-9.
97. Brasseur F, Rimoldi D, Lienard D, Lethe B, Carrel S, Arienti F et al. Expression of MAGE genes in primary and metastatic cutaneous melanoma. Int J Cancer 1995; 63: 375-80.
98. Greulich KM, Utikal J, Peter RU, Krahn G. c-MYC and nodular malignant melanoma. A case report. Cancer 2000; 89: 97-103.
99. Hipfel R, Schittek B, Bodingbauer Y, Garbe C. Specifically regulated genes in malignant melanoma tissues identified by subtractive hybridization. Br J Cancer 2000; 82: 1149-57.
100. Polsky D, Young AZ, Busam KJ, Alani RM. The transcriptional repressor of p16/Ink4a, Idl, is up-regulated in early melanomas. Cancer Res 2001; 61: 6008-11.
101. van der Velde-Zimmerman D, Roijers JF, Bouwens-Rombouts A, De Weger RA, de Graaf PW, Tilanus MG, Van den Tweel JG. Molecular test for the detection of tumor cells in blood and sentinel nodes of melanoma patients. Am J Pathol 1996; 149: 759-64.
102. Martenson ED, Hansson LO, Nilsson B, von Schoultz E, Mansson BE, Ringborg U, Hansson J. Serum S-100b protein as a prognostic marker in malignant cutaneous melanoma. J Clin Oncol 2001; 19: 824-31.
103. Palmieri G, Strazzullo M, Ascierto PA, Satriano SM, Daponte A, Castello G. Polymerase chain reaction-based detection of circulating melanoma cells as an effective marker of tumor progression. Melanoma Cooperative Group. J Clin Oncol 1999; 17: 304-11.
104. Schittek B, Blaheta HJ, Ellwanger U, Garbe C. Polymerase chain reaction in the detection of circulating tumour cells in peripheral blood of melanoma patients. Recent Results Cancer Res 2001; 158: 93-104.
105. Schrader AJ, Probst-Kepper M, Grosse J, Kunter U, Franzke A, Sel S, Atzpodien E, Buer J. Tumour microdissemination and survival in metastatic melanoma. Anticancer Res 2000; 20: 3619-24.
106. Schrader AJ, Probst-Kepper M, Grosse J, Kunter U, Schenk F, Franzke A et al. Molecular and prognostic classification of advanced melanoma: a multi-marker microcontamination assay of peripheral blood stem cells. Melanoma Res 2000; 10: 355-62.
107. Curry BJ, Myers K, Hersey P. MART-1 is expressed less frequently on circulating melanoma cells in patients who develop distant compared with locoregional metastases. J Clin Oncol 1999; 17: 2562-71.
108. Karakousis CP. Therapeutic node dissections in malignant melanoma. Semin Surg Oncol 1998; 14: 291-301.
109. Sharpless SM, Das Gupta TK. Surgery for metastatic melanoma. Semin Surg Oncol 1998; 14: 311-18.
110. Reintgen D. Establishing a standard of care for the patient with melanoma. Ann Surg Oncol 2001; 8: 91.
111. Reintgen D. Melanoma nodal metastases: biologic significance and therapeutic considerations. Surg Oncol Clin N Am 1996; 5: 105-20.
112. Bieligk SC, Ghossein R, Bhattacharya S, Coit DG. Detection of tyrosinase mRNA by reverse transcription-polymerase chain reaction in melanoma sentinel nodes. Ann Surg Oncol 1999; 6: 232-40.